Tamoxifen

Property	Information
Drug Name	Tamoxifen
FDA Approval	Yes (for breast cancer treatment)
Used for	Investigational use in glioblastoma (GBM) due to its inhibition of protein kinase C
Clinical Trial Phase	Phase II clinical trials and retrospective studies for GBM
Clinical Trial Explanation	Not specified
Common Side Effects	Blood clots, increased risk of uterine cancer in women, impotence and loss of libido in men, weight gain
OS without	Not specified
OS with	Data suggests tamoxifen may extend survival for certain glioblastoma patients, with specific outcomes depending on the study and patient demographics
PFS without	Not specified
PFS with	In studies, tamoxifen showed potential to improve progression-free survival for GBM patients under specific treatment regimens
Usefulness Rating	3
Usefulness Explanation	Not specified
Toxicity Level	3.5
Toxicity Explanation	Tamoxifen has been approved by FDA for breast cancer and while it is under investigation for glioblastoma, its high dosage use can lead to certain side effects. These include blood clots, potential risk of uterine cancer in women and impotence in men. Further, weight gain is also observed as a common side effect. Therefore, it is rated 3.5 in toxicity due to these common side effects and the potential serious health risks associated with its usage.

Notes: While primarily known for breast cancer treatment, tamoxifen's role in GBM focuses on its protein kinase C inhibition, offering a novel therapeutic avenue. High-dosage use, distinct from breast cancer treatment, necessitates careful management of side effects. Early clinical evidence points to a potential for improved outcomes in GBM treatment, warranting further research to optimize use and identify responsive patient groups.

From Ben Williams Book: Not specified

Loading comments...